Numerous multimonth clinical studies demonstrate a clinically meaningful reduction in fasting serum glucose, insulin, and HbA1c for a gel‐forming fiber versus placebo in patients with metabolic syndrome and type 2 diabetes (Cicero et al., 2010; Dall'Alba et al., 2013; Feinglos et al., 2013; Gibb, McRorie, Russell, Hasselblad, & D'Alessio, 2015; Tosh, 2013; Ziai et al., 2005). This evidence concerns the gene INS and metabolic syndrome.